The information in this section is intended for visitors outside the United States.
Gilead is inspired by the work that our grantees do to improve access and eliminate barriers to healthcare, advance education among patients and healthcare professionals, and help build strong local communities. Gilead supports projects across all of our therapeutic areas — HIV/AIDS, liver diseases, hematology and oncology, inflammatory and respiratory diseases, and cardiovascular conditions.
Continual advances in medical research mean millions of people with HIV are living longer, more fulfilling lives today. But HIV continues to have a devastating impact, especially on people who belong to underserved communities and who lack access to medical care. Gilead supports organizations working to help individuals learn their status and get the care they need. We also support organizations looking to solve the challenges of tomorrow, including how to:
Gilead works to address the HIV epidemic by discovering transformative and life-saving medicines, developing simplified treatment regimens that increase efficacy, expanding access to treatment for those who need it most and building communities among people affected by HIV and AIDS. Continuing on this commitment, Gilead will partner with and support institutions, community groups and organizations that are engaged in HIV cure activities by providing grant funding.
If you are interested in applying for an HIV cure grant, please click here to view the funding opportunity announcement and instructions on how to apply for funding. After reviewing the funding opportunity, those interested will need to submit a Letter of Intent to firstname.lastname@example.org before May 1, 2016, when inquiries for this round of funding are due.
Pre-exposure prophylaxis, or PrEP, involves the use of antiretroviral medication by HIV-negative individuals to remain uninfected. This prevention strategy has proved effective in clinical trials in reducing the risk of contracting HIV, and three major health organizations, the World Health Organization, Centers for Disease Control and Prevention, and the U.S. Panel of the International Antiviral (formerly AIDS) Society, have indicated that PrEP can have a significant impact on the reduction of HIV transmission rates among high-risk populations.
Gilead provides grant funding to organizations that support the efforts of community-based organizations, public health entities and similar umbrella organizations to educate their members about PrEP’s role as part of a comprehensive HIV prevention plan.
In line with our belief that Gilead medicines should be accessible to all who need them, regardless of their ability to pay, Gilead has accelerated efforts to help ensure PrEP is implemented safely and effectively. Gilead provides grants and support to community organizations, demonstration projects and research efforts that help raise awareness about PrEP among at-risk populations.
Hepatitis C kills more people in the U.S. than HIV does each year, yet public awareness of this disease remains limited because of its disproportionate impact on drug users, ethnic minorities and other at-risk groups. Gilead is working to change this by funding organizations that raise awareness of the importance of testing and access to care among these groups, as well as those that:
Gilead is proud to support the Vietnamese American Cancer Foundation (VACF), a grantee that has done tremendous work to eradicate HCV and HBV among the 300,000-plus Vietnamese-Americans living in Southern California. Its unique outreach programs, including a weekly radio show and in-person seminars with volunteer physicians, are helping Vietnamese-Americans overcome the stigma that has led to alarmingly high HCV rates within their communities.
Most adults in the U.S. have met or have known at least one cancer victim or survivor. Cancer remains one of the greatest health challenges we face, especially as the population ages. While there is no cure yet, education and awareness are powerful tools for detecting and treating the disease, and Gilead supports organizations that work to:
Lymphoma Research Foundation (LRF) applies its Gilead grant to a variety of marketing and outreach activities that educate patients and caregivers with disease-specific information and updates on treatment options and clinical trials, culminating in more than 120 educational programs annually that reach nearly 600,000 people online and offline.
From cystic fibrosis (CF) to influenza, inflammatory and respiratory diseases have a substantial impact on people of every age, gender, ethnic group and economic class. Gilead funds organizations that work in this therapeutic area to:
After one life-changing trip halfway around the world, Brian Callanan established the Cystic Fibrosis Lifestyle Foundation (CFLF) to share his new, more holistic approach to fighting the effects of the disease with other CF sufferers. CFLF uses a Gilead grant to provide its own grants to CF patients across the country, enabling them to manage their illness by pursuing their favorite physical activities.
As the U.S. population continues to age, cardiovascular health becomes an increasingly critical health concern. Cardiovascular conditions is one of Gilead’s growing therapeutic areas for grantee funding, for which Gilead supports organizations that work to:
WomenHeart: The National Coalition of Women with Heart Disease (WomenHeart), is the only patient-centered organization supporting women living with health disease through national health education campaigns and free nationwide patient support services. Its Gilead grant sponsors the WomenHeart Science & Leadership Symposium at Mayo Clinic, an annual event that teaches women living with heart disease to become the “boots on the ground” in the fight against heart disease and to work in unity as ambassadors who can help all women take charge of their heart health.
If you're new to the application process, learn how to apply here.
Existing users login here.